

CMBI Credit Commentary

Fixed Income Daily Market Update 固定收益部市场日报

- *Market sentiment was firm this morning. Asian IG space tightened c5bps and we saw buying flows on AMC/T2 and KR names. Developers FUTLAN/FTLNHD/VNKRLE were unchanged to 0.6pt higher.*
- *LPKRIJ: Ready to redeem LPKRIJ 8.125 01/22/25 in Jan'25. LPKRIJ'25 was unchanged this morning. See below comments.*
- *SINOCH: Sinochem is being investigated by Italian government over a potential breach of rules to curb its influence over Pirelli. We believe that the investigation will have immaterial impact to Sinochem given the 37% stakes in Pirelli only a small part of Sinochem's total assets of cUSD115bn. SINOCHs were unchanged to 4bps tighter this morning.*

❖ Trading desk comments 交易平台市场观点

Yesterday, UST curve bear-steepened and the yields widened 7-17bps amid the US presidential election. The flows in Asia IG space were under better buying after the UST moved higher. HYUELE/LGENSO/DAESEC/KOROIL/KORELE 27-34s were 4-8bps tighter. Meanwhile KRKPCS 27-29s tightened 9-10bps. In Chinese IGs, BABA/TENCNT/HAOHUA 30-31s tightened 3-8bps. MEITUA/ZHOSHK 28-30s were 4-6bps tighter. XIAOMI/LENOVO 30-31s tightened 5-7bps. In financials, FRESHKs tightened 8-10bps. Chinese AMC were mixed. CCAMCLs/ORIEASs were 5bps tighter. HRINTH 25-26s widened 1-3bps. EU AT1s were under one-way buying from Asian RMs/AMs. BACR 8/HSBC 8/SOCGEN 8.5 Perps were 0.1-0.4pt higher. However in insurance hybrids, NIPLIF '53/ZURNVX '55/FUKOKU Perp were 0.2-0.4pt lower in light of higher UST rates. In HK, BNKEA/NANYAN T2s closed 5-10bps tighter. AIA/CKHH 33-34s were 5-8bps tighter. NWDEVL 4.8/NANFUN 5 FFL Perps were down 0.3-0.4pt. In Chinese properties, SHUION 25-26s rose 0.5-1.0pt following the set-up of new Limited Partnership to restructure the investment holding structure and the proceeds from the transaction will be used to repay near-term offshore debts. ROADKG 28-30s/Perps were 0.4-0.7pt higher. In Macau gaming, MPELs/SANLTDs were 0.2-0.5pt lower. Outside China, GLPSP Perps were up 0.3-0.4pt. In Indonesia, LPKRIJ expects to redeem its USD63.7mn LPKRIJ 8.125 01/22/25 at maturity using the proceeds from stakes sales of Siloam Int'l Hospitals, per its earnings call. LPKRIJ '25 was unchanged. See comments below.

In SOE perps, the recent new CHPWCN 4.65/SPICPD 4.95 Perps were 0.1pt lower amid higher UST rates. COFCHK 3.1 Perp was down 0.1pt, while SPICPT 3.45 Perp was up 0.1pt. The flows skewed to better buying in LGFVs. There were onshore RMs picking up high-yielding LGFVs across CNH and USD papers. KMRLGP '24/GXCMI '25/LIANYU '25 were up 0.1pt.

Glenn Ko, CFA 高志和
(852) 3657 6235
glennko@cmbi.com.hk

Cyrena Ng, CPA 吳蔭瑩
(852) 3900 0801
cyrenang@cmbi.com.hk

Jerry Wang 王世超
(852) 3761 8919
jerrywang@cmbi.com.hk

❖ Last Trading Day's Top Movers

Top Performers	Price	Change	Top Underperformers	Price	Change
SHUION 5 1/2 06/29/26	86.1	1.0	DBJJP 3.749 12/18/48	76.5	-2.4
ROADKG 5 1/8 01/26/30	39.8	0.7	SINOPE 4.6 09/12/48	93.2	-2.3
ROADKG 5.9 09/05/28	47.3	0.7	HAOHUA 5 1/2 03/14/48	100.4	-2.2
ROADKG 5.2 07/12/29	40.8	0.5	DBJJP 3.46 04/23/49	71.9	-2.2
ROADKG 7.95 PERP	19.8	0.5	SUMIBK 6.184 07/13/43	108.6	-2.1

❖ Marco News Recap 宏观新闻回顾

Macro – S&P (+2.53%), Dow (+3.57%) and Nasdaq (+2.95%) were strong on Wednesday. China Oct'24 export/import was +12.7%/-2.3% yoy, compared with the expectation of +5.0%/-2.0% yoy. UST yield rallied higher yesterday, 2/5/10/30 yield reached 4.27%/4.27%/4.42%/4.60%.

❖ Desk Analyst Comments 分析员市场观点

➤ LPKRIJ: Ready to redeem LPKRIJ 8.125 01/22/25 in Jan'25

Lippo Karawaci (LPKR) will redeem LPKRIJ 8.125 01/22/25 of USD63.7mn (cIDR1tn) at maturity, to be funded by the remaining sale proceeds of 18.57% stakes in Siloam International Hospital (Siloam) of IDR6.9tn (cUSD437mn) in Sep'24. LPKR used part of the sale proceeds to call LPKRIJ 6.75 10/31/26 of USD130.8mn (cIDR2.1tn) at par on 31 Oct'24, and repaid syndicated loan of IDR525bn in 3Q24. The remaining of the proceeds of IDR3tn were used for other corporate purposes. We are neutral on LPKRIJ 8.125 01/22/25, the only outstanding USD bonds of LPKR, in view of tight valuation and thin trading liquidity. At 100.4, LPKRIJ 8.125 01/22/25 was traded at YTM of 5.7%.

LPKR started to deconsolidate Siloam since 13 Jun'24 and Siloam is accounted as an associate after the completion of 10.4% stake sale then to reduce ownership in Siloam below 50%. LPKR sold another 18.57% stakes in Sep'24 to cut its ownership in Siloam down to 29.09%. As a result of the deconsolidation, the 9M24 revenue and gross profit of LPKR dropped by 25% yoy to IDR9.3tn and 23% yoy to IDR4.1tn, respectively. LPKR recorded PBT of IDR19tn in 9M24, increased from IDR1.8tn in 9M23, thanks to the one-off gain from sales of Siloam stakes of IDR21.1tn. LPKR would have recorded LBT of IDR2.2tn if excluding the one-off gain. Moreover, LPKR's operating cash flow increased to IDR1.1tn in 9M24 from IDR662mn in 9M23, with lower payment to suppliers during the period.

On a standalone basis, Siloam's revenue and underlying net profit were both up by 11% yoy in 9M24 from 9M23, supported by higher inpatient admission and outpatient visits. To LPKR, we understand that the profit from Siloam was IDR280bn 1H24 (incl. share of profit post deconsolidation), and IDR129bn in 3Q24. We expect Siloam will continue to be an important part of LPKR's business portfolio, despite LPKR's ownership dropped to 29.09%. That said, LPKR could further monetize its shareholdings in Siloam in case of necessary.

LPKR achieved IDR4.3tn marketing sales in 9M24, represented 79% of FY24 marketing sales target. This reflected its good sales execution and pricing strategies in a generally soft market. The revenue from real estate segment stood at IDR3.2tn at 9M24 and 9M23. Besides, the revenue from lifestyle segment increased by 14% yoy in 9M24, supported by improved hotel occupancy and average room rates. On the other hand, we acknowledged that the share of losses from Lippo Malls Indonesia Retail Trust (LMIRT) in 9M24 was IDR278bn, and LPKR has no intention to change its stakes in LMIRT. LPKR currently owns 47.29% stakes in LMIRT. During the analyst briefing yesterday, LPKR refused to comment on the financial situations of LMIRT.

➤ **Offshore Asia New Issues (Priced)**

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
No Offshore Asia New Issues Priced Today					

➤ **Offshore Asia New Issues (Pipeline)**

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
No Offshore Asia New Issues Pipeline Today					

➤ **News and market color**

- Regarding onshore primary issuances, there were 73 credit bonds issued yesterday with an amount of RMB59bn. As for Month-to-date, 302 credit bonds were issued with a total amount of RMB320bn raised, representing a 44.3% yoy increase
- **[ADROIJ]** Fitch withdrew Adaro Indonesia's BBB- rating
- **[GEMDAL]** Gemdale Oct'24 contracted sales down 49% yoy to RMB5.6bn
- **[LINREI]** Link REIT 1H24 revenue rose 6.4% yoy to USD920.3mn and net property income rose 5.8% yoy to USD689.5mn
- **[PTTGC]** PTT Global Chemical 9M24 revenue rose 3.8% yoy to USD14bn and adj.EBITDA rose 3.1% yoy to USD865mn
- **[SHNSUN]** Shinsun Holdings (Group) share listing on HKEx to be cancelled with effect from 11 November 2024
- **[SINOCH]** Media reported that Sinochem Holdings is being investigated by Italian government over a potential breach of rules designed to curb its influence over Pirelli

Fixed Income Department

Tel: 852 3657 6235/ 852 3900 0801

fis@cmbi.com.hk

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.